Tvardi Therapeutics
TVRD
161 hedge funds and large institutions have $425M invested in Tvardi Therapeutics in 2020 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 32 increasing their positions, 48 reducing their positions, and 17 closing their positions.
88% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 17
56% more call options, than puts
Call options by funds: $6.17M | Put options by funds: $3.94M
10% more funds holding
Funds holding: 146 → 161 (+15)
0.04% more ownership
Funds ownership: 1.94% → 1.98% (+0.04%)
24% less capital invested
Capital invested by funds: $559M → $425M (-$134M)
33% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 48
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$5.4M |
| 2 |
Goldman Sachs
New York
|
+$4.72M |
| 3 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$4.25M |
| 4 |
First Manhattan
New York
|
+$3.45M |
| 5 |
Renaissance Technologies
New York
|
+$3.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.35M |
| 2 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$4.11M |
| 3 |
D.E. Shaw & Co
New York
|
-$3.1M |
| 4 |
C
Chescapmanager
Baltimore,
Maryland
|
-$2.74M |
| 5 |
CG
Carmignac Gestion
Paris,
France
|
-$2.57M |
TVRD Hedge Fund Activity: Q3 2020 in Review
161 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q3 2020, worth a combined $425M — down 24% from $559M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new TVRD positions and 17 closed out — a net gain of 15 holders — while 32 added to existing stakes and 48 trimmed.
The largest buyer was Jacobs Levy Equity Management, adding an estimated $5.4M. The largest seller was T. Rowe Price Associates, cutting an estimated $8.35M.
- 161 institutional investors held Tvardi Therapeutics (TVRD) as of Q3 2020, up from 146 in Q2 2020.
- Funds reported $425M of Tvardi Therapeutics stock for Q3 2020, down 24% quarter-over-quarter.
- 32 funds opened new Tvardi Therapeutics positions in Q3 2020 and 17 closed out, a net change of +15 holders.
- The largest Tvardi Therapeutics buyer in Q3 2020 was Jacobs Levy Equity Management, an estimated $5.4M added.
- The largest Tvardi Therapeutics seller in Q3 2020 was T. Rowe Price Associates, an estimated $8.35M sold.
Based on aggregated 13F filings for Q3 2020.